OTEZLA (Amgen Australia Pty Ltd)
Product name
OTEZLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
183 (255 working days)
Active ingredients
apremilast
Registration type
EOI
Indication
- The treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
- The treatment of adult patients with oral ulcers associated with Behçet’s Disease who are candidates for systemic therapy.